Last update April 16, 2015
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
B-577; Bay-d-1107; TV-485; TVX-485; WHR-5020 is also known as Etofenamate. Here it is a list of alternative known names::
B-577; Bay-d-1107; TV-485; TVX-485; WHR-5020 belongs to this group or family:
|Oral Bioavail.||21 (dermal)||%|
|Tmax||2 - 5.6||hours|
|T½||1.6 - 3.3||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a non-steroidal anti-inflammatory which is derived from Flufenamic acid, topically used but it can also be orally or intravenously administered.
At latest update relevant data related to breastfeeding were not found. However, we have information on its precursor the Flufenamic acid which is excreted into breast milk in non-significant amount and considered by the American Academy of Pediatrics as usual compatible with breastfeeding.
Absorption from skin to the plasma has been reported.
A high protein-binding capacity makes excretion into breast milk highly unlikely. However, it would be safer for both the mother and the infant the use of anti-inflammatory products with a proven safety while breastfeeding.
Avoid the use on the nipple or on extensive skin areas or long-term treatments to prevent systemic absorption.